WO2023079538A1 - A novel process for preparation of 5-hydroxy-5-aryl-pyrrol-2-ones and their intermediates - Google Patents

A novel process for preparation of 5-hydroxy-5-aryl-pyrrol-2-ones and their intermediates Download PDF

Info

Publication number
WO2023079538A1
WO2023079538A1 PCT/IB2022/060743 IB2022060743W WO2023079538A1 WO 2023079538 A1 WO2023079538 A1 WO 2023079538A1 IB 2022060743 W IB2022060743 W IB 2022060743W WO 2023079538 A1 WO2023079538 A1 WO 2023079538A1
Authority
WO
WIPO (PCT)
Prior art keywords
formula
compound
amine
solvent
pyrrol
Prior art date
Application number
PCT/IB2022/060743
Other languages
French (fr)
Inventor
Balaram P.N.
Vineeth VINAYAK
Original Assignee
Pnb Vesper Life Science Pvt Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pnb Vesper Life Science Pvt Limited filed Critical Pnb Vesper Life Science Pvt Limited
Priority to CN202280074562.3A priority Critical patent/CN118265697A/en
Publication of WO2023079538A1 publication Critical patent/WO2023079538A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/58One oxygen atom, e.g. butenolide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36Oxygen or sulfur atoms
    • C07D207/382-Pyrrolones

Definitions

  • the present invention is related to a process for preparation of 5-hydroxy-5-aryl-pyrrol-2- ones and their arylated furanones.
  • the present invention also relates to a two-stage process for preparation of 5-hydroxy-5-aryl-pyrrol-2-ones, particularly 4-chloro-5- hydroxy-l-substituted-5-arylated-lH-pyrrol-2(5H)-ones.
  • the arylated furanone intermediates are prepared by a Lewis acid catalysed Friedel Crafts reaction.
  • the active pharmaceutical ingredient (API) is obtained by a lactonisation reaction from the intermediate.
  • the 5-hydroxy-5-aryl-pyrrol-2-ones class of compounds have been reported to act as Cholecystokinin (CCK) receptor ligand.
  • CCK Cholecystokinin
  • the Indian patent application 1994/CHE/2011 describes compounds having a 5-hydroxy- 5-arylpyrrol-2-one core structure that are disclosed therein as having CCK binding activity. Further, it discloses a method for preparation of 5-hydroxy-5-aryl-pyrrol-2-ones, 15 compounds and their binding with the receptor.
  • arylated furanone intermediates and the final compounds obtained according to of the present invention are obtained in high yield and purity, produce less number of undesirable by-products being formed in the synthesis.
  • An embodiment of the present invention provides a process for preparation of 5- hydroxy5-aryl-pyrrol-2-ones of formula (I)
  • X is selected from hydrogen, a hydroxyl group, a halogen which is selected from fluorine, chlorine, bromine and iodine; preferably chlorine and most preferred fluorine and R is selected from isobutyl, benzyl and phenyl-ethyl; the process comprising; a) reacting of a mucohalic acid with benzene or substituted benzene in the presence of a Lewis acid in a haloalkane solvent to obtain the compound of formula (II) b) reacting the compound of formula (II) with a combination of a suitable amine and a trialkyl amine in an organic solvent to obtain the compound of formula (I),
  • An embodiment of the present invention provides a process for preparation of a compound of formula (II) comprising: reacting a mucohalic acid with benzene or a substituted benzene in the presence of a Lewis acid in a haloalkane solvent to obtain a compound of formula (II) wherein, X is selected from hydrogen, a hydroxyl group or a halogen.
  • Another embodiment of the present invention relates to a process for the preparation of 5- hydroxy5-aryl-pyrrol-2-ones of formula (I) from a compound of formula (II) comprising: treating a compound of formula (II) with a combination of primary amine and a tertiary amine in an organic solvent to obtain a compound of formula (I) wherein, X is selected from hydrogen, a hydroxyl group or a halogen; and R is selected from isobutyl, benzyl, phenyl or alkylated phenyl.
  • mucohalic acid refers to the group of halogenated furanones, particularly 2,3-dihalogenomalealdehydeic acids, including mucochloric acid (2,3- Dichloromalealdehydic acid) and mucobromic acid (2,3-Dibromomalealdehydic acid).
  • the mucohalic acid is mucochloric acid
  • X is fluorine
  • R is isobutyl or an alkylated phenyl such as benzyl or phenylethyl.
  • Another embodiment of the present invention provides a process for preparation of 5- hydroxy-1 -substituted -5-aryl-lH-pyrrol-2(5H)-one comprising; a) Reacting mucochloric acid with benzene in the presence of aluminum chloride in a halohydrocarbon solvent to obtain the compound of formula (III), b) treating the compound of formula (III) or formula (IV) with primary amines c) Formation and purification of 5-hydroxy-l-substituted-5-aryl-lH-pyrrol-2(5H)-ones in presence of a tertiary amine such as triethyl amine.
  • One embodiment of the present invention provides a process for preparation of the compound of formula (I): wherein X is selected from hydrogen, a hydroxyl group, a halogen which is selected from fluorine, chlorine, bromine and iodine; preferably chlorine and fluorine; and R is selected from isobutyl, benzyl and phenyl -ethyl.
  • An embodiment of the present invention provides a process for preparation of a compound of formula (II) comprising: reacting a mucohalic acid with benzene or a substituted benzene in the presence of a Lewis acid in a haloalkane solvent to obtain a compound of formula (II) wherein, X is selected from hydrogen, a hydroxyl group or a halogen.
  • Another embodiment of the present invention relates to a process for the preparation of 5- hydroxy5-aryl-pyrrol-2-ones of formula (I) from a compound of formula (II) comprising: treating a compound of formula (II) with a combination of primary amine and a tertiary amine in an organic solvent to obtain a compound of formula (I)
  • the process according to the present invention comprises: a) reacting a mucohalic acid with benzene or substituted benzene in the presence of a Lewis acid in a halohydrocarbon solvent to obtain the compound of formula (II) b) reacting the compound of formula (II) with a combination of primary and tertiary amine in an organic solvent to obtain the compound of formula (I).
  • process according to the present invention may optionally further comprise purifying the compound of formula (I) and/or isolating.
  • the process of the present invention comprises a process of purification of the compound of formula (I), said process comprising the steps of: a) dissolving the compound of formula (I) in a halo-hydrocarbon solvent to obtain a solution, b) distillation of the solution under vacuum at a temperature in the range of 30-50°C to obtain a solid, c) drying the solid, and d) recrystallising the compound of formula (I) from the solid.
  • the halo-hydrocarbon solvent used in this purification of compound of formula (I) may be is selected from trichloromethane, dichloromethane, 1,2 -dichloroethane or combinations thereof.
  • the recrystallising of the compound of formula I may be carried out using toluene or using ethanol/water mixture
  • X is a halogen selected from fluorine, chlorine, bromine and iodine, preferably chlorine and fluorine, most preferably fluorine.
  • R is isobutyl, phenyl, ethyl and alkylated phenyl, such as benzyl and phenylethyl groups.
  • X is fluorine and R isobutyl and alkylated phenyl, such as benzyl and phenylethyl groups.
  • X is fluorine and R isobutyl and alkylated phenyl, such as benzyl and phenylethyl.
  • the mucohalic acid selected from mucochloric acid or mucobromic acid, preferably mucochloric acid.
  • LA Lewis acid
  • DCM dichloromethane
  • the reaction of mucohalic acid with benzene or substituted benzene is carried out in the presence of a Lewis acid, which is selected from aluminum chloride, ferric chloride and zinc chloride and the like; preferably aluminum chloride.
  • a Lewis acid which is selected from aluminum chloride, ferric chloride and zinc chloride and the like; preferably aluminum chloride.
  • Anhydrous aluminium chloride is the most preferred (LA) Lewis acid.
  • the haloalkane solvent is a chloroalkane solvent selected from chloromethane, dichloromethane, trichloromethane, dichloroethane and the like; preferably dichloromethane.
  • chloromethane a chloroalkane solvent selected from chloromethane, dichloromethane, trichloromethane, dichloroethane and the like; preferably dichloromethane.
  • Presence of ethers such as tetrahydrofuran(THF), Methyl tert-butyl (MTB) ether and diethylether resulted in lower yields due to increased formation of byproducts.
  • a co-solvent selected from a range of haloaklanes particularly chlorinated chloroalkane solvents surprisingly suppressed the formation of the bisarylated by products in the intermediate preparation step.
  • the final step resulting in the preparation of the active compound the presence of equimolar ratio of an auxiliary amine and the suppression of the 4- substituted by-products. This allowed the process to become cleaner and economically more viable.
  • the present invention relates to a novel process towards the furanone intermediate (II) from mucohalic acids using chlorinated co-solvents to control the formation of intermediate (II) over bis-arylated acids by products.
  • chlorinated alkane is (DCM) dichloromethane.
  • the present invention relates to a novel process to convert the intermediate furanones of formula (II) with primary amines into 5 -hydroxy- IH-pyrrol- 2(5H)-ones (I) in presence of tertiary amines, most preferred (TEA) trimethylamine, comprising; a) reacting mucochloric acid with arenes or substituted benzenes in the presence of Lewis acid in haloalkane solvent to obtain the compound of formula (II) b) Reaction of compound of formula (II) with a suitable amine/ trialkyl amine combination in an organic solvent to obtain the compound of formula (I) c) Formation of 5-hydroxy-l-substituted-5-aryl-lH-pyrrol-2(5H)-ones of formula (1) in presence of a tertiary amine such as triethyl amine / trisopropylamine, most preferred TEA and purification therof.
  • a tertiary amine such as
  • the present invention relates to the synthesis of compounds of formula (I) in the presence of an equimolar ratio of an auxiliary amine and the suppression of the 4- substituted by-products.
  • the reaction intermediates for formula (II) may be isolated or converted further in situ into the compounds of formula (I).
  • recrystallisation of API compounds of formula (I) from toluene provided amorphous material with improved bioavailability.
  • Recrystallisation of API compounds of formula (I) from aqueous alcohol mixtures provided crystalline material ideal for purification of API (I) towards pharmaceutical grade purity.
  • the intermediate compound of formula (II) is further purified.
  • the purification is carried out using a solvent such as dimethylether, diethylether, tetra hydro furan (THF) or hexane.
  • the process step of treating the intermediate compound of formula (II) with an amine/trialkylamine combination in an organic solvent is carried out at a temperature in the range of -10 to 50°C.
  • the primary amine is selected from benzylamine, fluorobenzylamine, isopropylamine and phenylethylamine.
  • the tertiary amine is a triaklyl amine is selected from triethyl amine and triisopropylamine.
  • the primary amine is in the range of 1.1 to 3 molar equivalents by molecular weight to the tertiary amine; preferably about 1.2 equivalents.
  • the tertiary amine is in the range of 1.1 -1.5 equivalents by molecular weight to the primary amine.
  • the primary amine and tertiary amine are used in equimolar ratios.
  • the process as claimed in claim 2 wherein the organic solvent is selected from ether and halo-hydrocarbon or combinations thereof.
  • the organic solvent is an ether, preferably methyltertiarybutyl ether.
  • compound of formula (I) is further isolated using any conventional method such as precipitation or solvent evaporation.
  • Another embodiment of the present invention provides a process for preparation of 5- hydroxy-1 -substituted -5-aryl-lH-pyrrol-2(5H)-one comprising; a) Reacting mucochloric acid with benzene in the presence of aluminum chloride in a halohydrocarbon solvent to obtain the compound of formula (III),
  • the reaction of mucochloric acid with benzene in the presence of aluminum chloride is conducted at -10 to 40°C; preferably 0-10°C in dichloromethane solvent.
  • dichloromethane solvent was advantageous in terms of reducing the quantity of benzene as a solvent in this reaction stage. Further, solubility of these reactant in benzene solvent is lesser compared to use of dichloromethane. Therefore, use of dichloromethane resulted in complete solubility of the reactants and provides a better yield and a much improved purity of compounds of formula (III) and (IV).
  • 2-phenylethylamine with adjunct amine was reacted with the compound of formula (III) to form final API compound 5-hydroxy- l-phenethyl-5-phenyl-lH-pyrrol-2(5H)-one (API-1).
  • the reaction step of treating the compound of formula III with a primary amine is carried out in an organic solvent such as ether, esters, hydrocarbon; preferably methyl-tertiary-butyl ether.
  • chlorinated derivatives may be produced by the same process and they may be useful in other product applications.
  • the synthesis of the intermediate of formula (II) was carried out in the temperature range between -10°C and 40°C; Higher temperatures were avoided as the chlorinated solvent becomes reagent and by-products are formed, yield and purity is then decreased.
  • activated arenes such as benzene the temperature range from 4-10°C were most preferred.
  • halogenated arenes such as flurobenzene, the temperature was kept higher in the range from 15-20 C. Monitoring was maintained to avoid the formation of bisarylated arylic acids.
  • 3.4-dichloro-5-p-chlorophenylfuran-2(5H)-one was preferred by method 3 or 4 and most preferred by method 4.2.1.
  • Tetrachloromethane formed by-products and could not be used at low temperatures.
  • the dichloro-ethylen may replace dichloromethane.
  • Using sulphuric acid or performing the reaction at high temperatures resulted in higher production of the bis-arylated acids.
  • intermediate compounds of formula (II) may be further isolated. No chromatography is applied and furane intermediates (II) are most preferred isolated by crystallisation from hexane and toluene, not the usually reported alcohols as isopropanol and ethanol.
  • API formation and synthesis of hydroxypyrrolones (I) from arylated furanone intermediates (II) was carried out.
  • the reaction in this stage was conducted at -10°C-50°; preferably in steps below room temperature and then completion of conversion from lactone to lactame is achieved at 10-40°C.
  • Suitable amine was in the range of 1.1 to 3 equivalent by molecular weight; preferably about 1.2 equivalents was used in this reaction step to obtain higher yield in presence of 1.1-1.5 equivalent by molecular weight of tertiary amine.
  • the furanone system has various sites for attacks, such as the IPSO substitution in the 4- position and the lactonisation (5 position). Secondary amines react at the 4 and 5 position.
  • the combination of a primary with a tertiary amine resulted in increasing yield, provided API (I) in high purity and saved costs as amine in excess was only applied in equimolar range (1.1-1.2 eq).
  • Table 2 describes how the method for lactonisation was further optimised in a stepwise manner, leading to most preferred aprotic conditions and equimolar use of amine with tertiary amine adjunct and low reaction temperatures
  • Table 2 Optimisation of methods, API stage (I)
  • adjunct amines tri-isopropyl amine and triethyl amine were found chemically equivalent. They appear to be acting at various stages of the mechanism, a ring opening ring closure reaction, possibly via SN2‘ reaction.
  • the carboxylic acid may be activated by the adjunct amine, allowing the primary amine to form initially the amide and then via the shown tautomeric form of the allyl chloride structure, forming the lactone in high yield and very high purity.
  • the organic solvent selected from ether, halo-hydrocarbon etc was used in this step; preferably methyltertiarybutylether is used.
  • Polar solvents favour the reaction in the 4- position and secondary amine and gave a mixture of products.
  • Furanone intermediates of Formula (II) viz., 3,4-dichloro-5-phenylfuran-2(5H)-one (1-1), 3,4-dichloro-5-p-fluoro-phenylfuran-2(5H) one(I-2); 3,4-dichloro-5-p-chlorophenylfuran- 2(5H)-one (1-3) were synthesised, preferably by the optimised method 4 and most preferred by method 4.2.1 as mentioned in Table 1 above.
  • Aluminium chloride (296.4 gram) was added to the reactor to form a suspension in dichloromethane (2500ml).
  • Mucochloric acid 250 gm was added into a reaction flask.
  • 0-5°C benzene 275 ml was added and stirred for 150 minutes at 0- 10°C.
  • the reaction mass was quenched with concentrated 25 HC1 (0.75 litre) and stirred for 30 minutes.
  • the layers were separated and the organic layer was washed with water followed by the organic layers were combined and distilled out under vacuum at 35-50°C.
  • Aluminium chloride (296.4 gram) was added to form a suspension in dichloromethane (2500ml)
  • Mucochloric acid 250 gm was added into a reaction flask. Subsequently at 5-10°C fluoro-benzene (270 ml) was added and stirred for 150 minutes at RT. The reaction mass was quenched with concentrated 25 HC1 (0.75 litre) and stirred for 30 minutes. The layers were separated and the organic layer was washed with water followed by the organic layers were combined and distilled out under vacuum at 35-50°C.
  • Aluminium chloride (296.4 gram) was added to a round bottom flask to form a suspension in dichloromethane (2500ml).
  • Mucochloric acid 250 gm was added into a reaction flask.
  • 5-10°C fluorobenzene 275 ml was added and stirred for 150 minutes at RT.
  • the reaction mass was quenched with concentrated 25 HC1 (0.75 litre) and stirred for 30 minutes.
  • the layers were separated and the organic layer was washed with water followed by the organic layers were combined and distilled out under vacuum at 35-50°C.
  • the intermediate compound 1-1 was added to a reaction flask containing methyltertiary butylether (1150 mL) at 10°C followed by 2-phenylethylamine (56 gram) and triethyl amine (58g) was added under stirring for 60 minutes at 0-10°C. Temperature was raised to 40°C and stirred for 2 hours. Water (1000 ml) was added to the reaction mass and the layers were separated. The organic layer was washed with water and then filtered. The filtrate containing the organic layer was distilled under vacuum at 50°C. Yield: 180 grams of 5-hydroxy-l-phenethyl-5-phenyl-lH-pyrrol-2(5H)-one (API-1).
  • the intermediate 1-2 was added to a reaction flask containing methyl-tertiary butylether (1150 mL) at 10°C followed by fluoro-benzylamine (56 gram) and triethyl amine (58g) was added under stirring for 60 minutes at 0-10°C. Temperature was raised to 40°C and stirred for 2 hours. Water (1000 ml) was added to the reaction mass and the layers were separated. The organic layer was washed with water and then filtered. The filtrate containing the organic layer was distilled under vacuum at 50°C.
  • API-1 The 5-hydroxy-l-phenethyl-5-phenyl-lH-pyrrol-2(5H)-one (API-1) and the other APIs were further purified by a method comprising; a) Dissolution of the API in halo- hydrocarbon solvent, preferably selected from trichloromethane, dichloromethane, 1,2- dichloroe thane and the like; b) Distillation of the solution obtained in step (a) under vacuum at 30-50°C, c) Drying the solid obtained in step (b); and d) re -crystallization of the API from toluene and washing with excess water.
  • halo- hydrocarbon solvent preferably selected from trichloromethane, dichloromethane, 1,2- dichloroe thane and the like
  • Distillation of the solution obtained in step (a) under vacuum at 30-50°C c) Drying the solid obtained in step (b); and d) re -crystallization of the API from toluen
  • the process according to the present invention provides 5-hydroxy-l-phenethyl-5- phenyllH-pyrrol-2(5H)-one, 4-Chloro-5-(phenyl)-5-hydroxy-l-isobuyl-l,5-dihydro- pyrrol-2-one; 4-Chloro-5-(4-fluoro-phenyl)-5-hydroxy-l-isobutyl-l,5-dihydro-pyrrol-2- one ; 4-Chloro-5 -(4-fluoro-phenyl) -5 -hydroxy- 1 -benzyl- 1 ,5 -dihydro-pyrrol-2 -one ; 4- Chloro-5-(4-fluoro-phenyl)-5-hydroxy-l-p-fluorobenzyl-l,5-dihydro-pyrrol-2-one; 4- Chloro-5-(4-phenyl)-5-hydroxy-l -phenethyl-1 ,5-dihydro-pyrrol-2
  • the present invention also covers a polymorph or amorphous form of 5 -hydroxy- 1- phenethyl-5-phenyl-lH-pyrrol-2(5H)-one and other APIs obtained according to the process disclosed herein. Recrystallisation from ethanol water mixtures provided highly crystalline material and the crystallisation from toluene provided us with amorphous powders. This applied to the series of API (I). Bioavailability is increased for the microcrystalline material and this is useful for the arylated examples, occurring a lower bioavailability in general compared to the alkylated examples.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

The present invention relates to a process for preparation of 5-hydroxy-5-aryl-pyrrol-2- ones of formula (I) from their intermediate arylated furanone intermediates of formula (II). The present invention relates to a two-stage process for preparation of 5-hydroxy-5-aryl- pyrrol-2-ones, particularly 4-chloro-5-hydroxy-l-substituted-5-arylated-1H-pyrrol-2(5H)- ones. In the first stage, the arylated furanone intermediates of formula (II) are prepared by a Lewis acid catalysed Friedel Crafts reaction in the presence of a haloalkane solvent. In the second stage, the final compound of formula (I), is obtained by a lactonisation reaction from the arylated furanone intermediates in the presence of a combination of primary amine and tertiary amine.

Description

A NOVEL PROCESS FOR PREPARATION OF 5-HYDROXY-5-ARYL- PYRROL-2-ONES AND THEIR INTERMEDIATES
FIELD OF THE INVENTION
The present invention is related to a process for preparation of 5-hydroxy-5-aryl-pyrrol-2- ones and their arylated furanones. The present invention also relates to a two-stage process for preparation of 5-hydroxy-5-aryl-pyrrol-2-ones, particularly 4-chloro-5- hydroxy-l-substituted-5-arylated-lH-pyrrol-2(5H)-ones. In the first stage, the arylated furanone intermediates are prepared by a Lewis acid catalysed Friedel Crafts reaction. In the second stage, the final compound, the active pharmaceutical ingredient (API) is obtained by a lactonisation reaction from the intermediate.
BACKGROUND OF THE INVENTION
The 5-hydroxy-5-aryl-pyrrol-2-ones class of compounds have been reported to act as Cholecystokinin (CCK) receptor ligand.
The Indian patent application 1994/CHE/2011 describes compounds having a 5-hydroxy- 5-arylpyrrol-2-one core structure that are disclosed therein as having CCK binding activity. Further, it discloses a method for preparation of 5-hydroxy-5-aryl-pyrrol-2-ones, 15 compounds and their binding with the receptor.
The preparation method disclosed in 1994/CHE/2011 is associated with certain drawbacks. The scale on which the disclosed method can be practiced is limited to a small scale only. Due to the exothermic nature of the reaction the same is not safe to be performed on a larger scale for it may result in an explosion of reactor or formation of class particles resulting from an overheated reactor. Therefore, the disclosed process is neither safe nor is it industrially or economically viable.
The addition of the Lewis acid is fine on a small scale, but on a large scale, it is very dangerous and additionally the HCL gas formation is uncontrollable which can have disastrous effects such as the tragic events of the Bhopal gas disaster. Furthermore, excessive usage of cancerogenic solvents such as benzene, which are used as reagent and solvent are also not advisable in terms of health and the environment. The solvent use of expensive fluorinated reagents in stage 1 to obtain the intermediate is not commercially viable. Similarly, the use of expensive amines at the final stage, in order to bind HCL gas, liberated during the lactonisation process, is also not commercially viable
In conclusion, there is a need in the prior art to obtain highly pure 5-hydroxy-5-aryl- pyrrol-2-ones using a safe, industrially viable and economically viable process for the preparing the intermediates and then leading up to the final compound stages.
OBJECTS OF THE INVENTION
It is an object of the present invention to provide an improved process for the preparation 5-hydroxy5-aryl-pyrrol-2-ones of formula (I), which is safe for industrial application, and is industrially and economically viable.
It is also an object of the present invention to provide an improved process for the preparation of arylated furanone intermediates, particularly 2(5H)-furanones by an improved Lewis acid catalysed Friedel Crafts reaction.
It is also an object of the present invention to provide an improved process for the preparation of 5-hydroxy5-aryl-pyrrol-2-ones of formula (I) from he arylated furanone intermediates by an improved lactonisation reaction.
The arylated furanone intermediates and the final compounds obtained according to of the present invention are obtained in high yield and purity, produce less number of undesirable by-products being formed in the synthesis.
SUMMARY OF THE INVENTION
An embodiment of the present invention provides a process for preparation of 5- hydroxy5-aryl-pyrrol-2-ones of formula (I)
Figure imgf000003_0001
Wherein, X is selected from hydrogen, a hydroxyl group, a halogen which is selected from fluorine, chlorine, bromine and iodine; preferably chlorine and most preferred fluorine and R is selected from isobutyl, benzyl and phenyl-ethyl; the process comprising; a) reacting of a mucohalic acid with benzene or substituted benzene in the presence of a Lewis acid in a haloalkane solvent to obtain the compound of formula (II)
Figure imgf000004_0001
b) reacting the compound of formula (II) with a combination of a suitable amine and a trialkyl amine in an organic solvent to obtain the compound of formula (I),
An embodiment of the present invention provides a process for preparation of a compound of formula (II) comprising: reacting a mucohalic acid with benzene or a substituted benzene in the presence of a Lewis acid in a haloalkane solvent to obtain a compound of formula (II)
Figure imgf000004_0002
wherein, X is selected from hydrogen, a hydroxyl group or a halogen.
Another embodiment of the present invention relates to a process for the preparation of 5- hydroxy5-aryl-pyrrol-2-ones of formula (I) from a compound of formula (II) comprising: treating a compound of formula (II)
Figure imgf000005_0001
with a combination of primary amine and a tertiary amine in an organic solvent to obtain a compound of formula (I)
Figure imgf000005_0002
wherein, X is selected from hydrogen, a hydroxyl group or a halogen; and R is selected from isobutyl, benzyl, phenyl or alkylated phenyl.
As used herein, mucohalic acid refers to the group of halogenated furanones, particularly 2,3-dihalogenomalealdehydeic acids, including mucochloric acid (2,3- Dichloromalealdehydic acid) and mucobromic acid (2,3-Dibromomalealdehydic acid).
In a preferred embodiment, the mucohalic acid is mucochloric acid, X is fluorine and R is isobutyl or an alkylated phenyl such as benzyl or phenylethyl. Another embodiment of the present invention provides a process for preparation of 5- hydroxy-1 -substituted -5-aryl-lH-pyrrol-2(5H)-one comprising; a) Reacting mucochloric acid with benzene in the presence of aluminum chloride in a halohydrocarbon solvent to obtain the compound of formula (III),
Figure imgf000006_0001
b) treating the compound of formula (III) or formula (IV) with primary amines c) Formation and purification of 5-hydroxy-l-substituted-5-aryl-lH-pyrrol-2(5H)-ones in presence of a tertiary amine such as triethyl amine.
DETAILED DESCRIPTION OF THE INVENTION
One embodiment of the present invention provides a process for preparation of the compound of formula (I):
Figure imgf000006_0002
wherein X is selected from hydrogen, a hydroxyl group, a halogen which is selected from fluorine, chlorine, bromine and iodine; preferably chlorine and fluorine; and R is selected from isobutyl, benzyl and phenyl -ethyl.
An embodiment of the present invention provides a process for preparation of a compound of formula (II) comprising: reacting a mucohalic acid with benzene or a substituted benzene in the presence of a Lewis acid in a haloalkane solvent to obtain a compound of formula (II)
Figure imgf000007_0001
wherein, X is selected from hydrogen, a hydroxyl group or a halogen.
Another embodiment of the present invention relates to a process for the preparation of 5- hydroxy5-aryl-pyrrol-2-ones of formula (I) from a compound of formula (II) comprising: treating a compound of formula (II)
Figure imgf000007_0002
with a combination of primary amine and a tertiary amine in an organic solvent to obtain a compound of formula (I)
Figure imgf000008_0001
wherein, X is selected from hydrogen, a hydroxyl group or a halogen; R is selected from isobutyl, benzyl, phenyl or alkylated phenyl. In an embodiment, the process according to the present invention comprises: a) reacting a mucohalic acid with benzene or substituted benzene in the presence of a Lewis acid in a halohydrocarbon solvent to obtain the compound of formula (II)
Figure imgf000008_0002
b) reacting the compound of formula (II) with a combination of primary and tertiary amine in an organic solvent to obtain the compound of formula (I).
In an embodiment the process according to the present invention may optionally further comprise purifying the compound of formula (I) and/or isolating.
In an embodiment the process of the present invention comprises a process of purification of the compound of formula (I), said process comprising the steps of: a) dissolving the compound of formula (I) in a halo-hydrocarbon solvent to obtain a solution, b) distillation of the solution under vacuum at a temperature in the range of 30-50°C to obtain a solid, c) drying the solid, and d) recrystallising the compound of formula (I) from the solid.
The halo-hydrocarbon solvent used in this purification of compound of formula (I) may be is selected from trichloromethane, dichloromethane, 1,2 -dichloroethane or combinations thereof. The recrystallising of the compound of formula I may be carried out using toluene or using ethanol/water mixture
In an embodiment, X is a halogen selected from fluorine, chlorine, bromine and iodine, preferably chlorine and fluorine, most preferably fluorine.
In an embodiment, R is isobutyl, phenyl, ethyl and alkylated phenyl, such as benzyl and phenylethyl groups.
In a preferred embodiment, X is fluorine and R isobutyl and alkylated phenyl, such as benzyl and phenylethyl groups.
In another preferred embodiment, X is fluorine and R isobutyl and alkylated phenyl, such as benzyl and phenylethyl.
In an embodiment, the mucohalic acid selected from mucochloric acid or mucobromic acid, preferably mucochloric acid.
In a preferred embodiment the LA (Lewis acid) is Aluminium chloride and most preferred solvent dichloromethane (DCM).
In an embodiment of the present invention, the reaction of mucohalic acid with benzene or substituted benzene is carried out in the presence of a Lewis acid, which is selected from aluminum chloride, ferric chloride and zinc chloride and the like; preferably aluminum chloride. Anhydrous aluminium chloride is the most preferred (LA) Lewis acid.
The haloalkane solvent is a chloroalkane solvent selected from chloromethane, dichloromethane, trichloromethane, dichloroethane and the like; preferably dichloromethane. Presence of ethers such as tetrahydrofuran(THF), Methyl tert-butyl (MTB) ether and diethylether resulted in lower yields due to increased formation of byproducts.
The use of a co-solvent selected from a range of haloaklanes particularly chlorinated chloroalkane solvents surprisingly suppressed the formation of the bisarylated by products in the intermediate preparation step. In the final step resulting in the preparation of the active compound the presence of equimolar ratio of an auxiliary amine and the suppression of the 4- substituted by-products. This allowed the process to become cleaner and economically more viable.
In another embodiment the present invention relates to a novel process towards the furanone intermediate (II) from mucohalic acids using chlorinated co-solvents to control the formation of intermediate (II) over bis-arylated acids by products. The most preferred chlorinated alkane is (DCM) dichloromethane.
In another embodiment, the present invention relates to a novel process to convert the intermediate furanones of formula (II) with primary amines into 5 -hydroxy- IH-pyrrol- 2(5H)-ones (I) in presence of tertiary amines, most preferred (TEA) trimethylamine, comprising; a) reacting mucochloric acid with arenes or substituted benzenes in the presence of Lewis acid in haloalkane solvent to obtain the compound of formula (II)
Figure imgf000010_0001
b) Reaction of compound of formula (II) with a suitable amine/ trialkyl amine combination in an organic solvent to obtain the compound of formula (I) c) Formation of 5-hydroxy-l-substituted-5-aryl-lH-pyrrol-2(5H)-ones of formula (1) in presence of a tertiary amine such as triethyl amine / trisopropylamine, most preferred TEA and purification therof.
In yet another embodiment the present invention relates to the synthesis of compounds of formula (I) in the presence of an equimolar ratio of an auxiliary amine and the suppression of the 4- substituted by-products. In another embodiment of the present invention, the reaction intermediates for formula (II) may be isolated or converted further in situ into the compounds of formula (I).
In another embodiment of the present invention, recrystallisation of API compounds of formula (I) from toluene provided amorphous material with improved bioavailability. Recrystallisation of API compounds of formula (I) from aqueous alcohol mixtures provided crystalline material ideal for purification of API (I) towards pharmaceutical grade purity.
In another embodiment of the present invention, the intermediate compound of formula (II) is further purified. The purification is carried out using a solvent such as dimethylether, diethylether, tetra hydro furan (THF) or hexane.
In embodiment of the present invention, the process step of treating the intermediate compound of formula (II) with an amine/trialkylamine combination in an organic solvent is carried out at a temperature in the range of -10 to 50°C. The primary amine is selected from benzylamine, fluorobenzylamine, isopropylamine and phenylethylamine. The tertiary amine is a triaklyl amine is selected from triethyl amine and triisopropylamine. The primary amine is in the range of 1.1 to 3 molar equivalents by molecular weight to the tertiary amine; preferably about 1.2 equivalents. In a preferred embodiment, the tertiary amine is in the range of 1.1 -1.5 equivalents by molecular weight to the primary amine. In another preferred embodiment, the primary amine and tertiary amine are used in equimolar ratios.
In yet another embodiment of the present invention, the process as claimed in claim 2, wherein the organic solvent is selected from ether and halo-hydrocarbon or combinations thereof. In a preferred embodiment, the organic solvent is an ether, preferably methyltertiarybutyl ether.
In yet another embodiment of the present invention compound of formula (I) is further isolated using any conventional method such as precipitation or solvent evaporation.
Another embodiment of the present invention provides a process for preparation of 5- hydroxy-1 -substituted -5-aryl-lH-pyrrol-2(5H)-one comprising; a) Reacting mucochloric acid with benzene in the presence of aluminum chloride in a halohydrocarbon solvent to obtain the compound of formula (III),
Figure imgf000012_0001
or (IV)
Figure imgf000012_0002
b) treating the compound of formula (III) with primary amines c) Formation and purification of 5-hydroxy-l-substituted-5-aryl-lH-pyrrol-2(5H)-ones of formula (I) in presence of a tertiary amine such as triethyl amine.
The reaction of mucochloric acid with benzene in the presence of aluminum chloride is conducted at -10 to 40°C; preferably 0-10°C in dichloromethane solvent. Use of dichloromethane solvent was advantageous in terms of reducing the quantity of benzene as a solvent in this reaction stage. Further, solubility of these reactant in benzene solvent is lesser compared to use of dichloromethane. Therefore, use of dichloromethane resulted in complete solubility of the reactants and provides a better yield and a much improved purity of compounds of formula (III) and (IV). 2-phenylethylamine with adjunct amine was reacted with the compound of formula (III) to form final API compound 5-hydroxy- l-phenethyl-5-phenyl-lH-pyrrol-2(5H)-one (API-1). The reaction step of treating the compound of formula III with a primary amine is carried out in an organic solvent such as ether, esters, hydrocarbon; preferably methyl-tertiary-butyl ether.
Control of rate of reaction allowed scale up and provided for the first time an industrially feasible and safe save process for the formation of the intermediates III and IV from mucochloric acid. Also, chlorinated derivatives may be produced by the same process and they may be useful in other product applications.
Surprisingly, it was found that about 2 equivalents of amine compound, one equivalent of primary amine and 1 eq. of a tertiary amine by molecular weight is sufficient to obtain the final compound in higher yield and purity.
A preferred embodiment of the present invention is depicted in the following Scheme I.
Figure imgf000013_0001
Scheme I. From mucochloric acid via arylated furanone intermediate towards hydroxy-pyrrolone API
The methods of the present invention are described in further detail in the by way of the examples.
EXAMPLE 1: INTERMEDIATE SYNTHESIS METHODS
In the first stage, the synthesis of the intermediate of formula (II) was carried out in the temperature range between -10°C and 40°C; Higher temperatures were avoided as the chlorinated solvent becomes reagent and by-products are formed, yield and purity is then decreased. For activated arenes, such as benzene the temperature range from 4-10°C were most preferred. For halogenated arenes, such as flurobenzene, the temperature was kept higher in the range from 15-20 C. Monitoring was maintained to avoid the formation of bisarylated arylic acids.
The introduction of a halogenated solvent, most preferably DCM was paramount in the commercial synthesis of the intermediates of formula (II). The addition of a catalyst to the mixture of mucochloric acid and benzene was damaging the reactor and plant and represents a critical danger to the plant, and the infrastructure and human life.
The addition of mucochloric acid as a solid to the mixture of benzene and lewis acid gave a higher percentage of the bisarylated impurity and a lower overall yield.
A large range of solvents and co-solvents were tested. When the arene was added we were able to control safely the exothermic process; a brown mass in particular with ethers was obtained.
The process described here in detail is giving high yields, excellent purity, thus converting the intermediate in situ. The crude material may be used directly and cheaply to prepare the final active compounds.
By adding arene in the end the bis-arylated by-products are minimised and the rate of the reactions were carefully monitored/controlled. DCM is the most preferred solvent. Other co-sol vents, such as MTB ether were not beneficial in the intermediate technical synthesis.
The process was further optimised as shown in Table 1 with respect to order of reagents, solvents and Lewis acid.
TABLE 1: Method optimisation Intermediate stage (II)
Figure imgf000014_0001
Figure imgf000015_0002
Process is applicable to muco-halogen acids and their cognate preparations
3.4-dichloro-5-phenylfuran-2(5H)-one, 3,4-dichloro-5-p-fluoro-phenylfuran-2(5H) one;
3.4-dichloro-5-p-chlorophenylfuran-2(5H)-one was preferred by method 3 or 4 and most preferred by method 4.2.1. Tetrachloromethane formed by-products and could not be used at low temperatures. The dichloro-ethylen may replace dichloromethane. Using sulphuric acid or performing the reaction at high temperatures resulted in higher production of the bis-arylated acids.
Figure imgf000015_0001
Scheme II. Intermediate formation of 2(5H)-furanones and bisarylated by-products. The intermediate compound of formula (II) is optionally purified using ether solvent selected from dimethylether, diethylether, THF and the like.
The intermediate compounds of formula (II) may be further isolated. No chromatography is applied and furane intermediates (II) are most preferred isolated by crystallisation from hexane and toluene, not the usually reported alcohols as isopropanol and ethanol.
Recrystallization with solvent hexane yielded preferable results, which was surprising, as the intermediate as lipophilic molecule should be recrystallized best from isopropanol in theory. Recrystallisation or co-distillation with alcohols was not found to be suitable as esters are formed as by-products by these purification attempts. If hexane is replaced by toluene the intermediate (II) may be in situ converted into pyrrolone (I) using the same reactor.
EXAMPLE 2: API SYNTHESIS METHOD - LACTONISATION
API formation and synthesis of hydroxypyrrolones (I) from arylated furanone intermediates (II) was carried out. The reaction in this stage was conducted at -10°C-50°; preferably in steps below room temperature and then completion of conversion from lactone to lactame is achieved at 10-40°C.
Suitable amine was in the range of 1.1 to 3 equivalent by molecular weight; preferably about 1.2 equivalents was used in this reaction step to obtain higher yield in presence of 1.1-1.5 equivalent by molecular weight of tertiary amine.
The addition of tertiary amines appeared as a key factor to save 1 eq of expensive amines as fluoro-benzyl amine. This also unexpectedly improved the yield and purity in the preparation of the API (I) from the intermediates (II). Inorganic bases, such as hydrogen carbonate led to complex mixtures.
All tertiary amines, such as trietylamine and tri-isopropyl amine accelerated the rate of lactonisation, thus allowing a reduction of the reaction temperature, which also led to cleaner API formation. Organic solvent
Figure imgf000017_0001
Scheme 3. Sites for nucleophilic attacks, role of adjunct amine, ring-opening ringclosure lactonisation The adjunct tertiary amine is controlling the selectivity of the nucleophilic attack of the primary amine. In addition, by reducing reactant amine for costly amines, such as fluorinated amines and expensive amines the production costs are reduced further.
The furanone system has various sites for attacks, such as the IPSO substitution in the 4- position and the lactonisation (5 position). Secondary amines react at the 4 and 5 position. The combination of a primary with a tertiary amine resulted in increasing yield, provided API (I) in high purity and saved costs as amine in excess was only applied in equimolar range (1.1-1.2 eq).
Table 2 describes how the method for lactonisation was further optimised in a stepwise manner, leading to most preferred aprotic conditions and equimolar use of amine with tertiary amine adjunct and low reaction temperatures Table 2: Optimisation of methods, API stage (I)
Figure imgf000018_0001
The adjunct amines, tri-isopropyl amine and triethyl amine were found chemically equivalent. They appear to be acting at various stages of the mechanism, a ring opening ring closure reaction, possibly via SN2‘ reaction. Here, the carboxylic acid may be activated by the adjunct amine, allowing the primary amine to form initially the amide and then via the shown tautomeric form of the allyl chloride structure, forming the lactone in high yield and very high purity.
The organic solvent selected from ether, halo-hydrocarbon etc was used in this step; preferably methyltertiarybutylether is used. Polar solvents favour the reaction in the 4- position and secondary amine and gave a mixture of products.
Most preferred is the reaction of primary amine (benzylamine, fluorobenzylamine, isopropylamine and phenylethylamine) in the presence of a tertiary amine (triethyl amine, triisopropylamine), present in equimolar ratios to be added as a mixture of amines.
Further isolation of compound of formula (I) can be done by a conventional isolation method such as precipitation, solvent evaporation etc. Using toluene, the process can be performed in situ.
The compounds of formula (I) are further isolated by recrystallization from a solvent preferably toluene and excessive washing with water removing by products and reactants. No chromatography is applied to this process also. The clean process under fully optimised reaction conditions makes sophisticated purification stages redundant. EXAMPLE 3: SYNTHESIS OF 2(5H)- FURANONE INTERMEDIATES 1-1, 1-2 AND 1-3
Furanone intermediates of Formula (II) viz., 3,4-dichloro-5-phenylfuran-2(5H)-one (1-1), 3,4-dichloro-5-p-fluoro-phenylfuran-2(5H) one(I-2); 3,4-dichloro-5-p-chlorophenylfuran- 2(5H)-one (1-3) were synthesised, preferably by the optimised method 4 and most preferred by method 4.2.1 as mentioned in Table 1 above.
Synthesis of Intermediate 1-1: 3,4-dichloro-5-phenylfuran-2(5H)-one (1-1)
Aluminium chloride (296.4 gram) was added to the reactor to form a suspension in dichloromethane (2500ml). Mucochloric acid (250 gm) was added into a reaction flask. Subsequently at 0-5°C benzene (275 ml) was added and stirred for 150 minutes at 0- 10°C. The reaction mass was quenched with concentrated 25 HC1 (0.75 litre) and stirred for 30 minutes. The layers were separated and the organic layer was washed with water followed by the organic layers were combined and distilled out under vacuum at 35-50°C.
To the residue, petroleum ether (2500 ml) was added and stirred for 60-120 minutes at 5- 10°C followed by the precipitation was filtered and washed with petroleum ether (500 mL) and dried. Yield: 160 grams.
Synthesis of Intermediate 1-2: 3,4-dichloro-5-p-fluoro-phenylfuran-2(5H) one(I-2)
Aluminium chloride (296.4 gram) was added to form a suspension in dichloromethane (2500ml)
Mucochloric acid (250 gm) was added into a reaction flask. Subsequently at 5-10°C fluoro-benzene (270 ml) was added and stirred for 150 minutes at RT. The reaction mass was quenched with concentrated 25 HC1 (0.75 litre) and stirred for 30 minutes. The layers were separated and the organic layer was washed with water followed by the organic layers were combined and distilled out under vacuum at 35-50°C.
To the residue, petroleum ether (2500 ml) was added and stirred for 60-120 minutes at 5- 10°C followed by the precipitation was filtered and washed with petroleum ether (500 mL) and dried. Yield: 120 grams. Synthesis of Intermediate 1-3: 3,4-dichloro-5-p-chlorophenylfuran-2(5H)-one
Aluminium chloride (296.4 gram) was added to a round bottom flask to form a suspension in dichloromethane (2500ml). Mucochloric acid (250 gm) was added into a reaction flask. Subsequently at 5-10°C fluorobenzene (275 ml) was added and stirred for 150 minutes at RT. The reaction mass was quenched with concentrated 25 HC1 (0.75 litre) and stirred for 30 minutes. The layers were separated and the organic layer was washed with water followed by the organic layers were combined and distilled out under vacuum at 35-50°C.
To the residue, petroleum ether (2500 ml) was added and stirred for 60-120 minutes at 5- 10°C followed by the precipitation was filtered and washed with petroleum ether (500 mL) and dried. Yield: 130 grams.
EXAMPLE 4: SYNTHESIS OF 5-HYDROXY5-ARYL-PYRROL-2-ONES OF FORMULA (I) [API-1 to API-7]
Synthesis of API-1:
The intermediate compound 1-1 was added to a reaction flask containing methyltertiary butylether (1150 mL) at 10°C followed by 2-phenylethylamine (56 gram) and triethyl amine (58g) was added under stirring for 60 minutes at 0-10°C. Temperature was raised to 40°C and stirred for 2 hours. Water (1000 ml) was added to the reaction mass and the layers were separated. The organic layer was washed with water and then filtered. The filtrate containing the organic layer was distilled under vacuum at 50°C. Yield: 180 grams of 5-hydroxy-l-phenethyl-5-phenyl-lH-pyrrol-2(5H)-one (API-1).
Purification 5-hydroxy-l-phenethyl-5-phenyl-lH-pyrrol-2(5H)-one:
The crude API-1 5-hydroxy-l-phenethyl-5-phenyl-lH-pyrrol-2(5H)-one (150 gram) obtained above was dissolved in dichloromethane (2300 ml) and washed with hyflo bed with dichloromethane (100 ml) followed by filtered through hyflo bed and top wash with dichloromethane (100 ml). The filtrate was distilled under vacuum at 45-50°C to obtain a solid. Water (900 mL) was added to the solid and stirred for 30 minutes, filtered and washed with water (100 mL). The wet solid was dried to obtain pure 5 -hydroxy- 1- phenethyl-5-phenyl-lH-pyrrol-2(5H)-one. Yield: 76 grams. Purity: 100% (by HPLC); Moisture content: 0.08%. Alternatively, the crude products may be recrystallized from toluene.
Synthesis of API-2:
The intermediate 1-2 was added to a reaction flask containing methyl-tertiary butylether (1150 mL) at 10°C followed by fluoro-benzylamine (56 gram) and triethyl amine (58g) was added under stirring for 60 minutes at 0-10°C. Temperature was raised to 40°C and stirred for 2 hours. Water (1000 ml) was added to the reaction mass and the layers were separated. The organic layer was washed with water and then filtered. The filtrate containing the organic layer was distilled under vacuum at 50°C. Yield: 160 grams of 4- Chloro-5-(4-fluoro-phenyl)-5-hydroxy-l-p-fhiorobenzyl-l,5-dihydro-pyrrol-2-one (API- 2). Tri-isopropylamine was used alternatively to triethylamine and yields and purity are not significantly different.
Purification:
10g of 4-Chloro-5 -(4-fluoro-phenyl)-5 -hydroxy- 1 -p-fluorobenzyl- 1 ,5 -dihydro-pyrrol-2- one was dissolved in a mixture of 60% water and 40% ethanol under reflux. Cooling overnight provided a crystalline material in very high purity (>99.7%). Alternatively, the crude material is heated in pure ethanol and 50% hot water was added to give an increasingly clouding mixture, from which crystals formed over night at RT. This crystalline material, re -crystallised from hot toluene, provided an amorphous powder.
The following final API molecules were also prepared through cognate method :
Figure imgf000021_0001
Figure imgf000022_0002
Figure imgf000022_0001
The 5-hydroxy-l-phenethyl-5-phenyl-lH-pyrrol-2(5H)-one (API-1) and the other APIs were further purified by a method comprising; a) Dissolution of the API in halo- hydrocarbon solvent, preferably selected from trichloromethane, dichloromethane, 1,2- dichloroe thane and the like; b) Distillation of the solution obtained in step (a) under vacuum at 30-50°C, c) Drying the solid obtained in step (b); and d) re -crystallization of the API from toluene and washing with excess water.
The process according to the present invention provides 5-hydroxy-l-phenethyl-5- phenyllH-pyrrol-2(5H)-one, 4-Chloro-5-(phenyl)-5-hydroxy-l-isobuyl-l,5-dihydro- pyrrol-2-one; 4-Chloro-5-(4-fluoro-phenyl)-5-hydroxy-l-isobutyl-l,5-dihydro-pyrrol-2- one ; 4-Chloro-5 -(4-fluoro-phenyl) -5 -hydroxy- 1 -benzyl- 1 ,5 -dihydro-pyrrol-2 -one ; 4- Chloro-5-(4-fluoro-phenyl)-5-hydroxy-l-p-fluorobenzyl-l,5-dihydro-pyrrol-2-one; 4- Chloro-5-(4-phenyl)-5-hydroxy-l -phenethyl-1 ,5-dihydro-pyrrol-2-one; 4-Chloro-5-(4- chloro-phenyl)-5-hydroxy-l-phenethyl-l,5-dihydro-pyrrol-2-one; 4-Chloro-5-(4-Fluoro- phenyl) -5 -hydroxy- 1 -phenethyl-1, 5-dihydro-pyrrol -2 -one having purity >99%; preferably>99.7%; more preferably >99% (by HPLC).
The present invention also covers a polymorph or amorphous form of 5 -hydroxy- 1- phenethyl-5-phenyl-lH-pyrrol-2(5H)-one and other APIs obtained according to the process disclosed herein. Recrystallisation from ethanol water mixtures provided highly crystalline material and the crystallisation from toluene provided us with amorphous powders. This applied to the series of API (I). Bioavailability is increased for the microcrystalline material and this is useful for the arylated examples, occurring a lower bioavailability in general compared to the alkylated examples.

Claims

CLAIMS We claim:
1. A process for preparation of a compound of formula (II) comprising: a) reacting a mucohalic acid with benzene or a substituted benzene in the presence of a Lewis acid in a haloalkane solvent to obtain a compound of formula (II)
Figure imgf000023_0001
wherein, X is selected from hydrogen, a hydroxyl group or a halogen.
2. A process for the preparation of 5-hydroxy5-aryl-pyrrol-2-ones of formula (I) from a compound of formula (II) comprising: a) treating a compound of formula (II)
Figure imgf000023_0002
with a combination of primary amine and a tertiary amine in an organic solvent to obtain a compound of formula (I)
Figure imgf000024_0001
wherein,
X is selected from hydrogen, a hydroxyl group or a halogen;
R is selected from isobutyl, benzyl, phenyl or alkylated phenyl.
3. The process according to claims 1 or 2, wherein the halogen is selected from fluorine, chlorine, bromine and iodine, preferably chlorine and fluorine.
4. The process as claimed in claim 2, wherein R is selected from isobutyl and phenyl-ethyl.
5. The process as claimed in claim 1, wherein the mucohalic acid is selected from mucochloric acid or mucobromic acid.
6. The process as claimed in claim 1, wherein the Lewis acid is selected from aluminium chloride, ferric chloride or zinc chloride, preferably aluminium chloride.
7. The process as claimed in claim 1, wherein the haloalkane solvent is a chloroalkane solvent selected from chloromethane, dichloromethane, trichloromethane and dichloroethane or combinations thereof, preferably dichloromethane.
8. The process as claimed in claim 1, wherein the step of reacting mucohalic acid with benzene or substituted benzene is carried out at a temperature in the range of about -10°C to 40°C, preferably between 0 to 20°C.
9. The process as claimed in claim 1, wherein the compound of formula (II) is further purified.
10. The process as claimed in claim 9, wherein the purification is carried out using a solvent selected from dimethylether, diethylether, tetra hydro furan (THF) and hexane or combinations thereof.
11. The process as claimed in claim 2, wherein the treating a compound of formula (II) with an amine/trialkylamine in an organic solvent is carried out at a temperature in the range of -10 to 50°C.
12. The process as claimed in claim 2, wherein the primary amine is selected from benzylamine, fluorobenzylamine, isopropylamine and phenylethylamine.
13. The process as claimed in claim 2, wherein the tertiary amine is a triaklyl amine is selected from triethyl amine and triisopropylamine.
14. The process as claimed in claim 2, wherein the primary amine is in the range of 1.1 to 3 molar equivalents by molecular weight to the tertiary amine; preferably about 1.2 equivalents.
15. The process as claimed in claim 2, wherein the tertiary amine is in the range of 1.1-1.5 equivalents by molecular weight to the primary amine.
16. The process as claimed in claim 2, wherein the primary amine and tertiary amine are used in equimolar ratios.
17. The process as claimed in claim 2, wherein the organic solvent is selected from ether and halo-hydrocarbon or combinations thereof.
18. The process as claimed in claim 17, wherein the organic solvent is an ether, preferably methyltertiarybutyl ether.
19. The process as claimed in claim 2, further comprising isolation of compound of formula (I) using any conventional method such as precipitation or solvent evaporation.
20. The process as claimed in claim 2, purifying the compound of formula (I), said process comprising the steps of: a) dissolving the compound of formula (I) in a halo-hydrocarbon solvent to obtain a solution, b) distillation of the solution under vacuum at a temperature in the range of 30-50°C to obtain a solid, c) drying the solid, and d) recrystallising the compound of formula (I) from the solid.
21. The process as claimed in claim 20, wherein the halo-hydrocarbon solvent is selected from trichloromethane, dichloromethane, 1,2 -dichloroethane or combinations thereof.
22. The process as claimed in claim 20, wherein recrystallising is carried out using toluene.
23. The process as claimed in claim 20, wherein the recrystallising is carried out using ethanol/water mixture.
24. A process for preparation of 5-hydroxy5-aryl-pyrrol-2-ones of formula (I) comprising: a) reacting a mucohalic acid with benzene or a substituted benzene in the presence of a Lewis acid in a haloalkane solvent to obtain a compound of formula (II); and
Figure imgf000026_0001
b) treating the compound of formula (II) with a combination of primary amine and a tertiary amine in an organic solvent to obtain a compound of formula (I)
Figure imgf000026_0002
wherein,
X is selected from hydrogen, a hydroxyl group or a halogen; and R is selected from isobutyl, benzyl, phenyl or alkylated phenyl.
25. The process as claimed in claim 24, wherein the halogen is selected from fluorine, chlorine, bromine and iodine, preferably chlorine and fluorine.
26. The process as claimed in claim 24, wherein R is selected from isobutyl and phenyl-ethyl.
27. The process as claimed in claim 24, wherein the mucohahc acid is selected from mucochloric acid or mucobromic acid, preferably mucochloric acid.
28. The process as claimed in claim 24, wherein the Lewis acid is selected from aluminium chloride, ferric chloride and zinc chloride, preferably aluminium chloride.
29. The process as claimed in claim 24, wherein the haloalkane solvent is a chloroalkane solvent selected from chloromethane, dichloromethane, trichloromethane and dichloroethane or combinations thereof, preferably dichloromethane.
30. The process as claimed in claim 24, wherein the step of reacting mucohalic acid with benzene or substituted benzene is carried out at a temperature in the range of about -10°C to 40°C, preferably between 0 to 20°C.
31. The process as claimed in claim 26, further comprising purification of the compound of formula (II).
32. The process as claimed in claim 35, wherein the purification is carried out using a solvent selected from dimethylether, diethylether, tetra hydro furan (THF) and hexane or combinations thereof.
33. The process as claimed in claim 24, wherein treating the compound of formula (II) with an amine/trialkylamine in an organic solvent is carried out at a temperature in the range of -10 to 50°C.
34. The process as claimed in claim 24, wherein the primary amine is benzylamine, fluorobenzylamine , isopropylamine and phenylethylamine.
35. The process as claim in claim 24, wherein the tertiary amine is a triaklyl amine is triethyl amine, triisopropylamine.
36. The process as claimed in claim 24, wherein the primary amine is in the range of
1.1 to 3 equivalents by molecular weight to the tertiary amine; preferably about
1.2 equivalents.
37. The process as claimed in claim 24, wherein the tertiary amine is in the range of 1.1-1.5 equivalents by molecular weight to the primary amine.
38. The process as claimed in claim 24, wherein the primary amine and tertiary amine are used in equimolar ratios.
39. The process as claimed in claim 24, wherein the organic solvent is selected from ether and halo-hydrocarbon or combinations thereof.
26 The process as claimed in claim 39, wherein the organic solvent is ether, preferably methyltertiarybutyl ether. The process as claimed in claim 24, further comprising isolating the compound of formula (I) using any conventional method such as precipitation or solvent evaporation. The process as claimed in claim 24, further comprising purification of the compound of formula (I), said process comprising the steps of: a. dissolving the compound of formula (I) in a halo-hydrocarbon solvent to obtain a solution, b. distillation of the solution under vacuum at a temperature in the range of 30-50°C to obtain a solid, c. drying the solid, and d. recrystallising the compound of formula (I) from the solid. The process as claimed in claim 45, wherein the halo-hydrocarbon solvent is selected from trichloromethane, dichloromethane, 1 ,2-dichloroethane or combinations thereof. The process as claimed in claim 45, wherein recrystallising is carried out using toluene. The process as claimed in claim 45, wherein the recrystallising is carried out using ethanol/water mixture. The process as claimed in any of claims 1-45, wherein the compound of formula
(I) is: a) 5-hydroxy-l-phenethyl-5-phenyl-lH-pyrrol-2(5H)-one, b) 4-Chloro-5-(4-fluoro-phenyl)-5-hydroxy-l -p-fluorobenzyl-1 ,5-dihydro- pyrrol-2-one, c) 4-Chloro-5 -(phenyl) -5 -hydroxy- 1 -isobuyl- 1 , 5 -dihydro-pyrrol-2 -one , d) 4-Chloro-5-(4-fluoro-phenyl)-5-hydroxy-l -isobutyl-1 ,5-dihydro-pyrrol- 2-one, e) 4-Chloro-5-(4-fluoro-phenyl)-5-hydroxy-l-benzyl-l,5-dihydro-pyrrol-2- one, f) 4-Chloro-5 -(4-fluorophenyl) -5 -hydroxy- 1 -phenethyl- 1 , 5 -dihydro-pyrrol- 2-one, or g) 4-Chloro-5-(4-chloro-phenyl)-5-hydroxy- 1 -phenethyl- 1 ,5-dihydro- pyrrol-2-one 1 The process as claimed in any of claims 1-45, wherein the compound of formula
(II) is: a) 3,4-dichloro-5-phenylfuran-2(5H)-one, b) 3,4-dichloro-5-p-fluoro-phenylfuran-2(5H) one; or c) 3,4-dichloro-5-p-chlorophenylfuran-2(5H)-one.
28
PCT/IB2022/060743 2021-11-08 2022-11-08 A novel process for preparation of 5-hydroxy-5-aryl-pyrrol-2-ones and their intermediates WO2023079538A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202280074562.3A CN118265697A (en) 2021-11-08 2022-11-08 Novel process for preparing 5-hydroxy-5-aryl-pyrrol-2-ones and intermediates therefor

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN202141020936 2021-11-08
IN202141020936 2021-11-08

Publications (1)

Publication Number Publication Date
WO2023079538A1 true WO2023079538A1 (en) 2023-05-11

Family

ID=86240992

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2022/060743 WO2023079538A1 (en) 2021-11-08 2022-11-08 A novel process for preparation of 5-hydroxy-5-aryl-pyrrol-2-ones and their intermediates

Country Status (2)

Country Link
CN (1) CN118265697A (en)
WO (1) WO2023079538A1 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140005248A1 (en) * 2012-07-02 2014-01-02 Padijarethakkal N Balaram Novel cholecystokinin receptor ligands

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140005248A1 (en) * 2012-07-02 2014-01-02 Padijarethakkal N Balaram Novel cholecystokinin receptor ligands

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LATTMANN ERIC, SATTAYASAI JINTANA, NARAYANAN RAMESH, BENYAMEN JULIAN, BALARAM P N, LATTMANN PORNTHIP: "CCK2-Gastrin Antagonist: Development of PNB-001 (4-Chloro-5-Hydroxy-1-Phenylethyl-5-Phenyl-1, 5-Dihydro-Pyrrol-2-one) as Anti-Inflammatory Analgesic", SAJ PHARMACY AND PHARMACOLOGY, vol. 2, no. 1, 12 April 2018 (2018-04-12), XP093065338, ISSN: 2375-2262 *

Also Published As

Publication number Publication date
CN118265697A (en) 2024-06-28

Similar Documents

Publication Publication Date Title
JP4236926B2 (en) Methanesulfonamide-benzofuran, its production method and use as a synthetic intermediate.
PL206029B1 (en) 2-butyl-3-(4-[3(dibutylamino)propoxy]benzoyl)-5-nitro-benzofuran hydrochloride and preparation thereof
SG176212A1 (en) Process for the production of dronedarone intermediates
EP2428511A1 (en) Synthesis of dronedarone and salts thereof
WO2011104591A1 (en) Novel process for the manufacture of dronedarone
WO2006080555A1 (en) Process for producing (z)-1-phenyl-1-(n,n-diethylamino­carbonyl)-2-phthalimidomethylcyclopropane
WO2023079538A1 (en) A novel process for preparation of 5-hydroxy-5-aryl-pyrrol-2-ones and their intermediates
KR20010022443A (en) A Process for the Preparation of Cyclopropylacetylene
EP3207023A2 (en) Process for the preparation of halo-substituted benzenes
WO2022097115A1 (en) An improved process for preparation of prohexadione and its calcium salt
JP4286524B2 (en) A method for producing 4-alkoxyphenyl-4-oxo-butyric acid and a method for producing 7-alkoxy-1-tetralones.
KR20040043176A (en) Process for the preparation of 5-substituted isobenzofurans
US7196197B2 (en) Process for the preparation of Flecainide, its pharmaceutically acceptable salts and important intermediates thereof
CA2730224A1 (en) Synthesis of 6,7-dihydro-1h-indeno[5,4-b]furan-8(2h)-one as intermediate in the preparation of ramelteon
JP3431218B2 (en) Preparation of chromancarboxylic acid derivatives
JP5424272B2 (en) Method for producing 9-hydroxymethyl-cyclohepta [b] pyridine-3-carboxylic acid ester derivative
US5969159A (en) Synthesis of cyclopentyl 2-thienyl ketone tiletamine and tiletamine acid addition salts such as tiletamine hydrochloride
JPH0511110B2 (en)
WO2008148599A2 (en) Process for obtaining a valsartan salt useful for obtaining valsartan
SK287721B6 (en) Process for producing quinoline carboxyaldehyde derivative and intermediate thereof
JP2006524247A5 (en)
WO2004035520A1 (en) Process for production of an acetylenic compound
CN116813508A (en) Method for synthesizing 5-halogeno-2-methylbenzoic acid with high selectivity
CN112174784A (en) Crystal form A of 1- (4-phenoxyphenoxy) -2-propanol and preparation method and application thereof
NZ542603A (en) Synthesis of 2-chloromethyl-6-methylbenzoic acid esters

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22889560

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 202280074562.3

Country of ref document: CN